EMA/414728/2014

European Medicines Agency decision

P/0180/2014

of 17 July 2014

on the acceptance of a modification of an agreed paediatric investigation plan for daclatasvir (EMEA-001191-PIP01-11-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0180/2014

of 17 July 2014

on the acceptance of a modification of an agreed paediatric investigation plan for daclatasvir (EMEA-001191-PIP01-11-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0166/2012 issued on 26 July 2012,

Having regard to the application submitted by Bristol-Myers Squibb International Corporation on 28 March 2014 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 June 2014, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for daclatasvir, chewable tablet, film-coated tablet, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Bristol-Myers Squibb International Corporation, Parc de l'Alliance, Avenue de Finlande 4, 1420 - Braine-l'Alleud, Belgium.

Done at London, 17 July 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/206850/2014 corr

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001191-PIP01-11-M01

Scope of the application

Active substance(s):

Daclatasvir

Condition(s):

Treatment of chronic hepatitis C

Pharmaceutical form(s):

Chewable tablet

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Bristol-Myers Squibb International Corporation

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Bristol-Myers Squibb International Corporation submitted to the European Medicines Agency on 28 March 2014 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0166/2012 issued on 26 July 2012.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 23 April 2014.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 20 June 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of chronic hepatitis C

The waiver applies to:

- The paediatric population from birth to less than 3 years of age;
- for film-coated tablet, chewable tablet, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of chronic hepatitis C

2.1.1. Indication(s) targeted by the PIP

Daclatasvir (DCV) in combination with sofosbuvir (SOF) is indicated for the treatment of children and adolescents from 3 years to less than 18 years of age with genotype (GT)-1 to -6 chronic hepatitis C, who are treatment-naïve or treatment-experienced.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Chewable tablet

2.1.4. Studies

Area	Number of studies	Description
Quality-related studies	1	Study 1: Development of an age-appropriate chewable tablet formulation.
Non-clinical studies	2	Study 2: Pre- and postnatal development study. Study 3: Ten-week oral toxicity study in juvenile rats.

Clinical studies	2	Study 4: Open-label, single-arm trial to evaluate pharmacokinetics (PK), safety, tolerability and efficacy of daclatasvir (DCV), asunaprevir (ASV) and BMS-791325 in combination in children from 3 to less than 18 years of age with chronic hepatitis C genotype (GT)-1b infection who are treatment-naïve. Study 5: Open-label, single-arm trial to evaluate pharmacokinetics, safety and efficacy of DCV in combination with sofosbuvir in children from 3 to less than 18 years of age with GT-1 to -6 chronic hepatitis C (CHC).
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes.
Date of completion of the paediatric investigation plan:	By September 2022.
Deferral for one or more studies contained in the paediatric investigation plan:	Yes.